Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ecnoglutide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    China Signs Off On Pfizer, Sciwind's GLP-1 Weight Loss Drug
    China Signs Off On Pfizer, Sciwind's GLP-1 Weight Loss Drug

    06 Mar 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/pfizer-breaks-obesity-market-china-approval-sciwind-partnered-glp-1

    FIERCE PHARMA
    06 Mar 2026
    Share Share
    NMPA Approves Sciwind's Ecnoglutide for Weight Management
    NMPA Approves Sciwind's Ecnoglutide for Weight Management

    06 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management-302706442.html

    PR NEWSWIRE
    06 Mar 2026
    Share Share
    Sciwind to Highlight Positive Results for Ecnoglutide and Amylin Analogs
    Sciwind to Highlight Positive Results for Ecnoglutide and Amylin Analogs

    21 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conference-302178846.html

    PR NEWSWIRE
    21 Jun 2024
    Share Share
    Sciwind Announces Publication of Phase 1 Clinical Trial Results of Ecnoglutide
    Sciwind Announces Publication of Phase 1 Clinical Trial Results of Ecnoglutide

    11 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-publication-of-discovery-preclinical-and-phase-1-clinical-trial-results-of-ecnoglutide-xw003-in-molecular-metabolism-301873994.html

    PR NEWSWIRE
    11 Jul 2023
    Share Share
    Sciwind to Highlight Positive Data for GLP-1 Peptide Agonist Ecnoglutide
    Sciwind to Highlight Positive Data for GLP-1 Peptide Agonist Ecnoglutide

    23 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-to-highlight-positive-clinical-data-for-glp-1-peptide-agonist-ecnoglutide-xw003-at-the-american-diabetes-association-ada-83rd-annual-conference-301858192.html

    PR NEWSWIRE
    23 Jun 2023
    Share Share
    Sciwind Announces Initiation of Patient Dosing in PIII Trials of Ecnoglutide
    Sciwind Announces Initiation of Patient Dosing in PIII Trials of Ecnoglutide

    30 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-initiation-of-patient-dosing-in-phase-3-clinical-trials-of-ecnoglutide-xw003-a-long-acting-glp-1-analog-for-the-treatment-of-type-2-diabetes-in-china-301733145.html

    PR NEWSWIRE
    30 Jan 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.